We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A receptor (hAR) antagonists to determine their kinetic profiles and affinities. Many compounds showed high affinities and a diverse range of kinetic profiles. We found hAR antagonists with very short residence time (RT) at the receptor (2.2 min for 5) and much longer RTs (e.g., 376 min for 27 or 391 min for 31). Two representative antagonists (5 and 27) were tested in [S]GTPγS binding assays, and their RTs appeared correlated to their (in)surmountable antagonism. From a k-k-K kinetic map, we divided the antagonists into three subgroups, providing a possible direction for the further development of hAR antagonists. Additionally, we performed a computational modeling study that sheds light on the crucial receptor interactions, dictating the compounds' binding kinetics. Knowledge of target binding kinetics appears useful for developing and triaging new hAR antagonists in the early phase of drug discovery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601358PMC
http://dx.doi.org/10.1021/acs.jmedchem.7b00950DOI Listing

Publication Analysis

Top Keywords

har antagonists
16
pyrido[21-f]purine-24-dione derivatives
8
derivatives human
8
human adenosine
8
adenosine receptor
8
kinetic profiles
8
binding kinetics
8
antagonists
7
structure-affinity relationships
4
relationships structure-kinetics
4

Similar Publications

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.

Int J Mol Sci

October 2024

Grupo de Investigación Cánceres de Origen Epitelial, Departamento de Biología de Sistemas, Campus Científico-Tecnológico, Universidad de Alcalá, 28805 Madrid, Spain.

Article Synopsis
  • The study investigates the combined effects of GHRH-R antagonist MIA-690 and EGFR inhibitor Gefitinib on advanced prostate cancer cells, as treating castration-resistant prostate cancer (CRPC) is challenging due to drug resistance.
  • Findings show that this combination therapy significantly reduces cell viability, adhesion, and metalloprotease activity, while also causing cell cycle arrest in prostate cancer PC-3 cells.
  • In vivo results from athymic nude mice confirm that the combined treatment is more effective against tumors than using either drug alone, by disrupting the interaction between GHRH-R and EGFR pathways.
View Article and Find Full Text PDF

Inhibitors of the interaction between Neuropilin-1 (NRP-1) and Vascular Endothelial Growth Factor-A (VEGF-A) hold significant promise as therapeutic and diagnostic agents directed against cancers overexpressing NRP-1. In our efforts in this field, a few series of strong and fairly stable peptide-like inhibitors of the general formula Lys(Har)-Xaa-Xaa-Arg have been previously discovered. In the current work, we focused on Lys(Har)-Dap/Dab-Pro-Arg sequence.

View Article and Find Full Text PDF

Acute pericardial postischemic inflammatory responses: Characterization using a preclinical porcine model.

Cardiovasc Pathol

September 2024

Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address:

Background: Pericardial fluid (PF) contains cells, proteins, and inflammatory mediators, such as cytokines, chemokines, growth factors, and matrix metalloproteinases. To date, we lack an adequate understanding of the inflammatory response that acute injury elicits in the pericardial space.

Objective: To characterize the inflammatory profile in the pericardial space acutely after ischemia/reperfusion.

View Article and Find Full Text PDF

GPCRs (G protein-coupled receptors), also known as 7 transmembrane domain receptors, are the largest receptor family in the human genome, with ≈800 members. GPCRs regulate nearly every aspect of human physiology and disease, thus serving as important drug targets in cardiovascular disease. Sharing a conserved structure comprised of 7 transmembrane α-helices, GPCRs couple to heterotrimeric G-proteins, GPCR kinases, and β-arrestins, promoting downstream signaling through second messengers and other intracellular signaling pathways.

View Article and Find Full Text PDF

Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the pan-human coronavirus antiviral activity and off-target selectivity profile of PF-07817883.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!